# US 2024/0197919 A1 · Recombinant aavs for delivery to central nervous system and brain vasculature

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197919 A1
- Document ID: US20240197919A1
- Status: Published application
- Kind: A1
- Application number: 18/288,910
- Filed: 2022-05-03
- Published: 2024-06-20
- Earliest claimed: 2021-05-04
- Applicants: California Institute of Technology
- Inventors: Viviana Gradinaru; Xinhong Chen
- Web page: https://patentgrep.com/patent/US20240197919A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/005: from viruses
- C07K 14/47: from mammals
- C12N 15/86: Viral vectors
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein include compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms to the central nervous system with increased specificity and transduction efficiency, including endothelial cells of the neurovascular unit. Also described include methods of treating various diseases and conditions using the rAAVs.

## Claims

### Claim 1

An adeno-associated virus (AAV) targeting peptide comprising an amino acid sequence that comprises at least 4 contiguous amino acids from a sequence selected from the group consisting of GNNTRSV (SEQ ID NO: 13), GNNTRDT (SEQ ID NO: 14) and TNSTRPV (SEQ ID NO: 15).

### Claim 2 (depends on 1)

The AAV targeting peptide of claim 1, wherein the targeting peptide comprises at least 5 contiguous amino acids from the sequence of GNNTRSV (SEQ ID NO: 13).

### Claim 3 (depends on 1)

The AAV targeting peptide of claim 1, wherein the targeting peptide comprises at least 6 contiguous amino acids from the sequence of GNNTRSV (SEQ ID NO: 13).

### Claim 4 (depends on 1)

The AAV targeting peptide of claim 1, wherein the targeting peptide comprises GNNTRSV (SEQ ID NO: 13).

### Claim 5 (depends on 1)

The AAV targeting peptide of claim 1, wherein the targeting peptide comprises at least 4 contiguous amino acids from the sequence GNNTRDT (SEQ ID NO: 14).

### Claim 6 (depends on 5)

The AAV targeting peptide of claim 5, wherein the targeting peptide comprises at least 5 contiguous amino acids from the sequence of GNNTRDT (SEQ ID NO: 14).

### Claim 7 (depends on 5)

The AAV targeting peptide of claim 5, wherein the targeting peptide comprises at least 6 contiguous amino acids from the sequence of GNNTRDT (SEQ ID NO: 14).

### Claim 8 (depends on 5)

The AAV targeting peptide of claim 5, wherein the targeting peptide comprises GNNTRDT (SEQ ID NO: 14).

### Claim 9 (depends on 1)

The AAV targeting peptide of claim 1, wherein the targeting peptide comprises at least 4 contiguous amino acids from the sequence TNSTRPV (SEQ ID NO: 15).

### Claim 10 (depends on 9)

The AAV targeting peptide of claim 9, wherein the targeting peptide comprises at least 5 contiguous amino acids from the sequence of TNSTRPV (SEQ ID NO: 15).

### Claim 11 (depends on 9)

The AAV targeting peptide of claim 9, wherein the targeting peptide comprises at least 6 contiguous amino acids from the sequence of TNSTRPV (SEQ ID NO: 15).

### Claim 12 (depends on 9)

The AAV targeting peptide of claim 9, wherein the targeting peptide comprises TNSTRPV (SEQ ID NO: 15).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The AAV targeting peptide of any one of claims 1-12, wherein the targeting AAV peptide is part of an AAV.

### Claim 14 (depends on 13)

The AAV targeting peptide of claim 13, wherein the targeting peptide is part of a capsid protein of the AAV.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The AAV targeting peptide of any one of claims 1-14, wherein the targeting peptide is conjugated to a nanoparticle, a second molecule, a viral capsid protein, or a combination thereof.
peptide is a central nervous system (CNS) targeting peptide.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An adeno-associated virus (AAV) capsid protein comprising an AAV targeting peptide of any one of claims 1-16.

### Claim 18 (depends on 17)

The AAV capsid protein of claim 17, further comprising at least 4 contiguous amino acids from a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 19 (depends on 17)

The AAV capsid protein of claim 17, further comprising at least 5 contiguous amino acids from a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 20 (depends on 17)

The AAV capsid protein of claim 17, further comprising at least 6 contiguous amino acids from a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 21 (depends on 17)

The AAV capsid protein of claim 17, further comprising a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 22 (depends on 18, 19, 20, 21)

The AAV capsid protein of any one of claims 18-21, wherein the at least 4, 5 or 6 contiguous amino acids from the second amino acid sequence replace at least 4, 5, 6 or 7 amino acids in AA452-458, or functional equivalents thereof, of the AAV capsid protein.

### Claim 23 (depends on 22)

The AAV capsid protein of claim 22, wherein the at least 4, 5 or 6 contiguous amino acids from the second amino acid sequence, or the second amino acid sequence, replace at least 4, 5, 6 or 7 amino acids in the 455 loop, or functional equivalents thereof, of the AAV capsid protein.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The AAV capsid protein of any one of claims 17-23, further comprising one or more of amino acid substitutions at position N272, S386, and W503.

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23)

The AAV capsid protein of any one of claims 17-23, further comprising one or more of amino acid substitutions N272A, S386A, W503A, and W503R.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The AAV capsid protein of any one of claims 17-25, wherein the AAV capsid is derived from AAV9, or a variant thereof.

### Claim 27 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25)

The AAV capsid protein of any one of claims 17-25, wherein the AAV capsid is derived from an AAV selected from the group consisting of AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, human isolate hu.31, human isolate hu.32, rhesus isolate rh.8, and rhesus isolate rh.10.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A nucleic acid, comprising a sequence encoding the AAV targeting peptide of any one of claims 1-16.
one of claims 17-27.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A recombinant adeno-associated virus (rAAV), comprising AAV targeting peptide of any one of claims 1-16, or an AAV capsid protein of any one of claims 17-27.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A recombinant adeno-associated virus (rAAV), comprising an AAV capsid protein which comprises the AAV targeting peptide of any one of claims 1-16, wherein the amino acid sequence is inserted between two adjacent amino acids in AA586-592, or functional equivalents thereof, of the AAV capsid protein.

### Claim 32 (depends on 31)

The rAAV of claim 31, wherein the two adjacent amino acids are AA588 and AA589.

### Claim 33 (depends on 30, 31, 32)

The rAAV of any one of claims 30-32, wherein the AAV capsid protein comprises, or consists thereof, SEQ ID NOs: 1 or 2.

### Claim 34 (depends on 30, 31, 32, 33)

The rAAV of any one of claims 30-33, further comprising at least 4 contiguous amino acids from a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 35 (depends on 30, 31, 32, 33)

The rAAV of any one of claims 30-33, further comprising at least 5 contiguous amino acids from a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 36 (depends on 30, 31, 32, 33)

The rAAV of any one of claims 30-33, further comprising at least 6 contiguous amino acids from a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 37 (depends on 30, 31, 32, 33)

The rAAV of any one of claims 30-33, further comprising a second amino acid sequence selected from the group consisting of DGQSSKS (SEQ ID NO: 17), DGAATKN (SEQ ID NO: 16), and LQTSSPG (SEQ ID NO: 18).

### Claim 38 (depends on 34, 35, 36, 37)

The rAAV of any one of claims 34-37, wherein the at least 4, 5, or 6 contiguous amino acids from a second amino acid sequence, or the second amino acid sequence, replace at least 4, 5, 6 or 7 amino acids in AA452-458, or functional equivalents thereof, of the AAV capsid protein.

### Claim 39 (depends on 34, 35, 36, 37)

The rAAV of any one of claims 34-37, wherein the at least 4, 5, or 6 contiguous amino acids from a second amino acid sequence, or the second amino acid sequence, replace at least 4, 5, 6 or 7 amino acids in the 455 loop, or functional equivalents thereof, of the AAV capsid protein.

### Claim 40 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The rAAV of any one of claims 30-39, further comprising one or more of amino acid substitutions at position N272, S386, and W503.
acid substitutions N272A, S386A, W503A, and W503R.

### Claim 42 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The rAAV of any one of claims 30-41, wherein the rAAV comprises an rAAV vector genome.

### Claim 43 (depends on 42)

The rAAV of claim 42, wherein the rAAV vector genome comprises one or more miRNA-122 (miR-122) binding sites.

### Claim 44 (depends on 43)

The rAAV of claim 43, wherein the one or more miR-122 binding sites are located in the 3′ UTR of the rAAV vector genome.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A composition, comprising
an AAV targeting peptide of any one of claims 1-16,
an AAV capsid protein of any one of claims 17-27,
a nucleic acid of any one of claims 28-29,
an rAAV of any one of claims 30-44, or a combination thereof.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the composition is a pharmaceutical composition comprising one or more pharmaceutical acceptable carriers.

### Claim 47 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A composition for use in the delivery of an agent to a target environment of a subject in need, comprising an AAV comprising (1) an AAV capsid protein of any one of claims 17-27 and (2) an agent to be delivered to the target environment of the subject, wherein the target environment is the nervous system.

### Claim 48 (depends on 47)

The composition for use of claim 47, wherein the target environment is the central nervous system (CNS), the peripheral nervous system (PNS), or a combination thereof.

### Claim 49 (depends on 47, 48)

The composition for use of any one of claims 47-48, wherein the target environment is brain endothelial cells, neurons, capillaries in the brain, arterioles in the brain, arteries in the brain, or a combination thereof.

### Claim 50 (depends on 47, 48, 49)

The composition for use of any one of claims 47-49, wherein the composition is a pharmaceutical composition comprising one or more pharmaceutical acceptable carriers.

### Claim 51 (depends on 47, 48, 49, 50)

The composition for use of any one of claims 47-50, wherein the agent to be delivered comprises a nucleic acid, a peptide, a small molecule, an aptamer, or a combination thereof.

### Claim 52 (depends on 51)

The composition for use of claim 51, wherein the nucleic acid comprises one or more of:
a) a DNA sequence that encodes a trophic factor, a growth factor, or a soluble protein;
b) a cDNA that restores protein function to humans or animals harboring a genetic mutation(s) in that gene;
or state of a cell;
d) a cDNA that encodes a protein or a nucleic acid that can be used for assessing the state of a cell;
e) a cDNA that encodes a protein for gene editing, or a guide RNA;
f) a DNA sequence for genome editing via homologous recombination;
g) a DNA sequence encoding a therapeutic RNA;
h) an shRNA or an artificial miRNA delivery system; and
i) a DNA sequence that influences the splicing of an endogenous gene.

### Claim 53 (depends on 47, 48, 49, 50, 51, 52)

The composition for use of any one of claims 47-52, wherein the subject in need is a subject suffering from or at a risk to develop one or more of chronic pain, Friedreich's ataxia, Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), spinal muscular atrophy types I and II (SMA I and II), Friedreich's Ataxia (FA), Spinocerebellar ataxia, multiple sclerosis (MS), chronic traumatic encephalopathy (CTE), HIV-1 associated dementia, or lysosomal storage disorders that involve cells within the CNS.

### Claim 54 (depends on 53)

The composition for use of claim 53, wherein the lysosomal storage disorder is Krabbe disease, Sandhoff disease, Tay-Sachs, Gaucher disease (Type I, II or III), Niemann-Pick disease (NPC1 or NPC2 deficiency), Hurler syndrome, Pompe Disease, or Batten disease.

### Claim 55 (depends on 47, 48, 49, 50, 51, 52)

The composition for use of any one of claims 47-52, wherein the subject in need is a subject suffering from, at risk to develop, or has suffered from a stroke, traumatic brain injury, epilepsy, or spinal cord injury.

### Claim 56 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition for use of any one of claims 47-55, wherein the composition is for intravenous administration.

### Claim 57 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition for use of any one of claims 47-55, wherein the composition is for systemic administration.

### Claim 58 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The composition for use of any one of claims 47-57, wherein the agent is delivered to endothelial lining of the ventricles in the brain, central canal of the spinal cord, capillaries in the brain, arterioles in the brain, arteries in the brain, or a combination thereof of the subject.

### Claim 59 (depends on 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The composition for use of any one of claims 47-58, wherein the subject is an adult animal.

### Claim 60 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of delivering an agent to a nervous system of a subject, the method comprising:
claims 17-27, wherein the AAV vector further comprises an agent to be delivered to the nervous system; and
administering the AAV vector to the subject.

### Claim 61 (depends on 60)

The method of claim 60, wherein the administration is a systemic administration.

### Claim 62 (depends on 60)

The method of claim 60, wherein the administration is an intravenous administration.

### Claim 63 (depends on 60, 61, 62)

The method of any one of claims 60-62, wherein the subject is a primate and the agent is delivered to the endothelial cells and neurons of the nervous system.

### Claim 64 (depends on 60, 61, 62, 63)

The method of any one of claims 60-63, wherein the agent is delivered to the endothelial cells of the nervous system of the subject at least 1.5-fold, 2-fold, or 3-fold more efficiently than the delivery of the agent to the neurons of the nervous system.

### Claim 65 (depends on 60, 61, 62, 63, 64)

The method of any one of claims 60-64, wherein the nervous system is the central nervous system (CNS).

### Claim 66 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of delivering an agent to a cell, the method comprising: contacting an AAV vector comprising an AAV capsid protein of any one of claims 17-27 with the cell, wherein the AAV vector further comprises an agent to be delivered to the nervous system, and wherein the cell is an endothelial cell or a neuron.

### Claim 67 (depends on 66)

The method of claim 66, wherein contacting the AAV vector with the cell occurs in vitro, in vivo or ex vivo.

### Claim 68 (depends on 66, 67)

The method of any one of claims 66-67, wherein the cell is present in a tissue, an organ, or a subject.

### Claim 69 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein the cell is a brain endothelial cell, a neuron, a cell in the capillaries in the brain, a cell in the arterioles of the brain, a cell in the arteries in the brain, a cell in the brain vasculature, or a combination thereof.

### Claim 70 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 60-69, wherein the agent to be delivered comprises a nucleic acid, a peptide, a small molecule, an aptamer or a combination thereof.

### Claim 71 (depends on 70)

The method of claim 70, wherein the nucleic acid encodes a therapeutic protein.

### Claim 72 (depends on 70)

The method of claim 70, wherein the nucleic acid comprises one or more of:
a) a DNA sequence that encodes a trophic factor, a growth factor, or other soluble factors capable of being released from the transduced cells and affect the survival or function of that cell and/or surrounding cells;
b) a cDNA that restores protein function to humans or animals harboring a genetic mutation(s) in that gene;
or state of a cell;
d) a cDNA that encodes a protein or a nucleic acid that can be used for assessing the state of a cell;
e) a cDNA that encodes a protein for gene editing, or a guide RNA;
f) a DNA sequence for genome editing via homologous recombination;
g) a DNA sequence encoding a therapeutic RNA;
h) an shRNA or an artificial miRNA delivery system; and
i) a DNA sequence that influences the splicing of an endogenous gene.

### Claim 73 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 60-72, wherein the AAV vector is an AAV9 vector, or a variant thereof.

### Claim 74 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 60-72, wherein the AAV vector is a vector selected from the group consisting of AAV1, AAV2, AAV3, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, human isolate hu.31, human isolate hu.32, rhesus isolate rh.8, rhesus isolate rh.10, or a variant thereof.

### Claim 75 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of any one of claims 60-74, wherein the serotype of the AAV vector is different from the serotype of the AAV capsid.

### Claim 76 (depends on 70, 71, 72, 73, 74, 75)

The method of any one of claims 70-75, wherein the nucleic acid comprises one or more miRNA-122 (miR-122) binding sites.

### Claim 77 (depends on 76)

The method of claim 76, wherein at least one of the one or more miR-122 binding sites is located in the 3′ UTR of the nucleic acid.
